2024
Clinical Course of Isolated Recurrent, Persistent Complex Perianal Fistulas without Luminal Crohn’s Disease: A Multicenter Case Series of 24 Patients
Fiske H, Tse C, Al-Bawardy B, Magavi P, Konijeti G, Mao E, Fine S, Parian A, Lazarev M, Shah S. Clinical Course of Isolated Recurrent, Persistent Complex Perianal Fistulas without Luminal Crohn’s Disease: A Multicenter Case Series of 24 Patients. Crohn's & Colitis 360 2024, otae065. DOI: 10.1093/crocol/otae065.Peer-Reviewed Original ResearchComplex perianal fistulasMulticenter case seriesPerianal fistulasIntensive surgical interventionClinical courseCrohn's diseaseCase seriesSurgical interventionPresumptive diagnosis of Crohn's diseaseClinical course of patientsEvidence of inflammatory bowel diseaseRetrospective multicenter case seriesPresentation of Crohn's diseaseLuminal Crohn's diseaseCourse of patientsOutcomes of patientsDiagnosis of Crohn's diseaseMedical-surgical approachInflammatory bowel diseaseComplex fistulasLuminal inflammationFistula closureCryptoglandular fistulasSurgical therapyBiologic therapyS1066 Outcomes of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Case Series of 24 Patients
Fiske H, Tse C, Al-Bawardy B, Magavi P, Konijeti G, Mao E, Fine S, Parian A, Lazarev M, Shah S. S1066 Outcomes of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Case Series of 24 Patients. The American Journal Of Gastroenterology 2024, 119: s752-s756. DOI: 10.14309/01.ajg.0001033632.76152.4b.Peer-Reviewed Original Research
2023
Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice
Gaidos J, Al Bawardy B, Farraye F, Regueiro M. Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice. Crohn's & Colitis 360 2023, 5: otad037. PMID: 37559746, PMCID: PMC10407976, DOI: 10.1093/crocol/otad037.Peer-Reviewed Original ResearchMayo endoscopic subscoreEndoscopic scoreEndoscopy scoresCrohn's diseaseRutgeerts scoreChi-square testPouchitis Disease Activity IndexDisease activity indexSimple Endoscopic ScoreEndoscopic scoring systemManagement of patientsPearson's chi-square testMore consistent useIBD practiceEndoscopic subscoreMucosal healingAdult gastroenterologistsMore frequent useUnpaired Student'sClinical practiceTreatment targetsScoring systemWeb-based surveyCase-based conferencesFurther evaluation
2022
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mosli M, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, Khardaly A, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease. Saudi Journal Of Gastroenterology 2022, 29: s1-s35. PMID: 36412460, PMCID: PMC10540981, DOI: 10.4103/sjg.sjg_277_22.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseManagement of IBDExpert opinion-based recommendationsManagement of adultsOpinion-based recommendationsLevel of evidenceEvidence-based interventionsIBD diagnosisUlcerative colitisCrohn's diseaseConsensus guidelinesConsensus guidanceOptimal managementClinical pharmacyDiseaseSaudi MinistryAdultsDiagnosisConcise guidelinesGuidelinesLiterature reviewTime of writingColitisPatientsImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDiseaseNovel and Emerging Therapies for Inflammatory Bowel Disease
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.BooksInflammatory bowel diseaseBowel diseaseAnti-tumor necrosis factorPotential systemic manifestationsSecondary treatment failureTreatment response ratesJanus kinase inhibitorSelective Janus kinase inhibitorNew therapeutic targetsEmerging TherapiesCurrent biologicsIntestinal inflammationSystemic manifestationsUlcerative colitisCrohn's diseaseTreatment failureSafety profileNecrosis factorTherapeutic targetResponse rateDiseaseKinase inhibitorsTarget agentsInhibitorsTolerability
2018
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/
2017
Endoscopic and Radiographic Assessment of Crohn's Disease
Al-Bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics Of North America 2017, 46: 493-513. PMID: 28838411, DOI: 10.1016/j.gtc.2017.05.005.BooksConceptsCrohn's diseaseFavorable long-term outcomeEndoscopic mucosal healingRadiologic scoring systemChronic inflammatory disordersLong-term outcomesObjective measuresRadiologic responseDisease activityClinical improvementMucosal healingClinical symptomsReduced hospitalizationsInflammatory disordersRadiographic assessmentTreatment targetsScoring systemScoring toolDiseaseMore objective measuresTherapyCorticosteroidsHospitalizationComplicationsInflammation